Literature DB >> 23503043

Biosimilars in IBD: hope or expectation?

Krisztina B Gecse1, Reena Khanna, Gijs R van den Brink, Cyriel Y Ponsioen, Mark Löwenberg, Vipul Jairath, Simon P L Travis, William J Sandborn, Brian G Feagan, Geert R A M D'Haens.   

Abstract

Mesh：

Substances：

Year:  2013        PMID： 23503043     DOI： 10.1136/gutjnl-2012-303824

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


× No keyword cloud information.
  11 in total

Review 1.  Biosimilars in rheumatology: current perspectives and lessons learnt.

Authors:  Thomas Dörner; Jonathan Kay
Journal:  Nat Rev Rheumatol       Date:  2015-08-18       Impact factor: 20.543

2.  Is extrapolation of the safety and efficacy data in one indication to another appropriate for biosimilars?

Authors:  Howard Lee
Journal:  AAPS J       Date:  2013-10-11       Impact factor: 4.009

Review 3.  New targets for mucosal healing and therapy in inflammatory bowel diseases.

Authors:  M F Neurath
Journal:  Mucosal Immunol       Date:  2013-10-02       Impact factor: 7.313

4.  The Role of Biosimilars in Inflammatory Bowel Disease.

Authors:  Sudarshan Paramsothy; Noa Krugliak Cleveland; Nada Zmeter; David T Rubin
Journal:  Gastroenterol Hepatol (N Y)       Date:  2016-12

Review 5.  Implementable strategies and exploratory considerations to reduce costs associated with anti-TNF therapy in inflammatory bowel disease.

Authors:  K T Park; Wallace V Crandall; Jacqueline Fridge; Ian H Leibowitz; Marc Tsou; Dana M H Dykes; Edward J Hoffenberg; Michael D Kappelman; Richard B Colletti
Journal:  Inflamm Bowel Dis       Date:  2014-05       Impact factor: 5.325

6.  Benefits, Concerns, and Future Directions of Biosimilars in Inflammatory Bowel Disease.

Authors:  Brian Feagan
Journal:  Gastroenterol Hepatol (N Y)       Date:  2017-12

7.  Rate and Predictors of Endoscopic Mucosal Healing in Biologic Naive Patients with Inflammatory Bowel Disease by Azathioprine Treatment: A Real World, 10 Years' Experience from a Single Centre in Turkey.

Authors:  Metin Basaranoglu; Atilla Ertan; Sanju Mathew; Sonia Michael Najjar; Aftab Ala; Ali Eba Demirbag; Hakan Senturk
Journal:  J Gastrointest Dig Syst       Date:  2016-08-31

8.  Infliximab versus ciclosporin for steroid-resistant acute severe ulcerative colitis (CONSTRUCT): a mixed methods, open-label, pragmatic randomised trial.

Authors:  John G Williams; M Fasih Alam; Laith Alrubaiy; Ian Arnott; Clare Clement; David Cohen; John N Gordon; A Barney Hawthorne; Mike Hilton; Hayley A Hutchings; Aida U Jawhari; Mirella Longo; John Mansfield; Jayne M Morgan; Frances Rapport; Anne C Seagrove; Shaji Sebastian; Ian Shaw; Simon P L Travis; Alan Watkins
Journal:  Lancet Gastroenterol Hepatol       Date:  2016-09

Review 9.  CT-P13: design, development, and place in therapy.

Authors:  Tommaso Gabbani; Simona Deiana; Vito Annese
Journal:  Drug Des Devel Ther       Date:  2017-06-06       Impact factor: 4.162

Review 10.  Current status of biosimilars in the treatment of inflammatory bowel diseases.

Authors:  Dong Il Park
Journal:  Intest Res       Date:  2016-01-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.